OTCPK:VXRTBiotechs
A Look At Vaxart’s (VXRT) Valuation As New Norovirus Breastfeeding Study Gains Attention
Why Vaxart’s Norovirus Data Matters for Investors
Vaxart (VXRT) has drawn fresh attention after npj Vaccines published Phase 1 data on its single dose, oral bivalent norovirus vaccine in postpartum, breastfeeding women, highlighting immune responses in both mothers and their infants.
See our latest analysis for Vaxart.
The new npj Vaccines publication comes after a strong 30 day share price return of 83.38% and 90 day share price return of 81.95%. However, the 1 year total shareholder return...